Transaction · 0001697316-26-000014

Bios Fund I, LP

BIOS Fund I, LP, DIR, reported a transaction classified as grant at ACTUATE THERAPEUTICS, INC. involving 368304.000000 shares for an estimated $0.00. Reported holdings after the transaction were 368304.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ADIR
ACTUACTUATE THERAPEUTICS, INC.
Trade date
Oct 28, 2026
Filing date
Oct 30, 2026
View on SEC Insider profile
Disclosed value$0Shares × reported price
Shares traded368k$0.00 per share
Holdings after368kIndirect · Directly held by Bios Clinical Opportunity Fund, LP
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

ACTU price since this filing

Daily closing prices, with the filing date and available return windows
ACTU · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +94.7%1w ago +47.4%1d ago +5.3%
Returns since7d30d90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
grant
Code A
Identifier
0001697316-26-000014
Warrant (Right to Buy)
Transaction date
Oct 28, 2026
Filed Oct 30, 2026, 07:37 PM · 2d delay
Shares
368,304 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
368,304 sh
Indirect · Directly held by Bios Clinical Opportunity Fund, LP

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Large Holdings Increase
Filing-only score

-12 points

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

How this score is calculated
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector Yes10% YesOther No
Footnotes & amended
  1. F1

    Pursuant to a letter agreement, dated as of October 2, 2026 and amended on October 16, 2026 (the "Letter Agreement"), between Actuate Therapeutics, Inc. (the "Issuer") and Bios Partners, L.P., on beha…

  2. F2

    A Warrant may be exercised only during the period ("Exercise Period") commencing on October 28, 2026 and terminating at 5:00 P.M., New York time on October 28, 2031 ("Expiration Date"). Each Warrant n…

  3. F3

    Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"…

  4. F4

    Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity…

  5. F5

    The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate…

Original filing · 0001697316-26-000014
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

ACTU